DiaTech Oncology Receives New York State Clinical Laboratory Permit

From the June 25, 2013 press release: DiaTech Oncology, a life sciences and clinical pathology laboratory company based in Nashville, Tenn., today announced that the company has received a Clinical Laboratory Permit from the New York State Department of Health (NYS DOH). DiaTech's predictive assay test - which guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient - is now available to patients and physicians in all 50 states.

"Receiving this permit is great news for cancer patients. It affirms that our CAP-accredited, CLIA-certified laboratory meets the highest standards for accurate and reliable clinical laboratory services."

In clinical trials and published research, use of DiaTech Oncology's test - theMiCK assayor Correct Chemo - has consistently shown an increase in complete or partial response rates, longer time to relapse and a trend to longer survival times for more than 50 types of cancers, including lung, breast, colorectal, stomach, prostate, liver, ovarian, esophageal, bladder, non-Hodgkin lymphoma, leukemia and other cancers.

"New York State has the most stringent requirements for laboratory test approval in the United States," saysGarry Latimer, DiaTech CEO. "Receiving this permit is great news for cancer patients. It affirms that our CAP-accredited, CLIA-certified laboratory meets the highest standards for accurate and reliable clinical laboratory services."

"DiaTech's predictive assay - the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing apoptotic cell death in the malignant cells of a particular cancer patient - is now available to more cancer patients and oncologists than ever before," statesDr. Cary Presant, DiaTech Chief Medical Officer. "Our clinical studies consistently reveal that patients treated with MiCK assay-guided chemotherapy demonstrate longer survival times and lower costs, and our studies are continuing to produce unexpected new leads for innovative therapeutic strategies."

DiaTech's patented MiCK assay measures apoptosis, or cell death, in the cancer cells of chemotherapy patients. Tumor cells are exposed to multiple doses of several chemotherapeutic drugs, either as single drugs or combinations. An algorithm monitors and computes the amount of cell death and determines a drug sensitivity "score" of the patients' tumor cells.

About DiaTech Oncology

From their website:

"DiaTech Oncology, based in Nashville, Tenn., is a life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient's cancer cells by chemotherapy. The only test on the market that evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective, the MiCK assay has successfully tested all types of cancer. The MiCK assay is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry." Online:www.diatech-oncology.com.